Literature DB >> 6541252

Coexistence of rheumatoid arthritis and sarcoidosis: difficulties encountered in the differential diagnosis of common manifestations.

S Fallahi, R D Collins, R K Miller, J T Halla.   

Abstract

Two patients with rheumatoid arthritis (RA) and sarcoidosis illustrate the dilemmas posed by their coexistence in the same patient. The first patient with classical RA developed iridocyclitis, interstitial lung disease and cranial neuropathies, initially attributed to extraarticular rheumatoid disease. Subsequent lung and skin biopsy revealed many granulomas consistent with sarcoidosis whereas synovium revealed changes typical for RA. In the second patient with cutaneous and pulmonary sarcoidosis development of persistent erosive polyarthritis and a subcutaneous nodule with typical pathology permitted the diagnosis of coexistent RA. These cases emphasize that uveitis alone or multiple cranial neuropathies are not features of RA and symptomatic interstitial lung disease in patients with RA warrants further investigation.

Entities:  

Mesh:

Year:  1984        PMID: 6541252

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Mutilating rheumatoid arthritis associated with sarcoidosis: a case report.

Authors:  M Takashita; T Torisu; Y Shinmori
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

2.  A case of mixed connective tissue disease combined with sarcoidosis.

Authors:  M Mizumoto; Y O Adachi; J Chihara; T Matsumoto; T Yamamoto; S Nakajima; T Yamamoto
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

3.  Concomitant Autoimmune Diseases in Patients With Sarcoidosis in Turkey.

Authors:  Fidan Yildiz; Şenol Kobak; Hüseyin Semİz; Mehmet Orman
Journal:  Arch Rheumatol       Date:  2020-01-08       Impact factor: 1.472

4.  Lymph node hyalinisation in rheumatoid arthritis and systemic sclerosis.

Authors:  W G McCluggage; H Bharucha
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.